Dasage Oral: Orally, 100 to 300 mg in 1 or 2 divided doses daily.
Brands
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Sparbact | IPCA | Sai Pharmaceuticals Ltd. | 200mg | 6 | Tablet | per tablet | KES 613.00 |
| Sparta | Alembic Products Ltd | Europa Healthcare Ltd. | 200mg | 6 | Tablet | per tablet | KES 1,085.00 |
| Sparx | Wockhardt International | Pharma Specialities Ltd. | 200mg | 6 | Tablet | per tablet | KES 522.00 |
Sparfloxacin More info
| Sparfloxacin | |
|---|---|
| Mode Of Action | interferes with bacterial DNA synthesis by inhibiting topoisomerase II (DNA gyrase) and topoisomerase IV. |
| Drug Indication | E.N.T., UTI, RTI, skin and soft tissues, bone, joint, GI, intra-abdominal, pelvic and severe infections, gonorrhoea. |
| Precautions | As for Ciprofloxacin. Concern over phototoxicity associated with sparfloxacin has led to restriction of its use in some countries; patients should be advised to avoid exposure to sunlight during, and for a few days after, sparfloxacin therapy, and to stop the drug immediately if phototoxicity occurs. |
| Contra-Indications | Children under 18 years, pregnancy and lactation, hepatic disorders, hypersensitivity to quinolones. |
| Side Effects | Local irritation at the site of injection, GI disturbances, dizziness, headache, tremor, confusion, convulsions, rashes, blurred vision, psychotic reactions, impaired vision, impaired taste and smell sensation, Stevens-Johnson syndrome, hot flushes, skin rashes, migraine, photosensitivity |
| Dosage | Orally, 100 to 300 mg in 1 or 2 divided doses daily. |
| Special Information | In vivo activity in experimental model of infection against Gram-positive and Gram-negative organisms was higher than that of ciprofloxacin. |
| Pregnancy Category | Category B3 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals show evidence of an increased occurrence of foetal damage, the significance of which is uncertain in human |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Fluoroquinolones |